sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Global Anti-Mullerian Hormone Test Market Size Study, by Product, by End-User, by Distribution, by Use, and Regional Forecasts 2024-2032

Global Anti-Mullerian Hormone Test Market Size Study, by Product, by...

Home / Categories / Healthcare
Global Anti-Mullerian Hormone Test Market Size Study, by Product, by End-User, by Distribution, by Use, and Regional Forecasts 2024-2032
Global Anti-Mullerian Hormone Test Market...
Report Code
RO1/103/2894

Publish Date
30/Aug/2024

Pages
200
PRICE
$ 1800/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 2350/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 2850/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
Global Anti-Mullerian Hormone (AMH) Test Market is valued at approximately USD 274.26 million in 2023 and is anticipated to grow with a healthy growth rate of more than 11.46% over the forecast period 2024-2032. AMH tests are crucial diagnostic tools in reproductive medicine, providing essential information about ovarian reserve, egg quantity, and potential fertility. These tests are particularly valuable in assessing conditions such as polycystic ovary syndrome (PCOS) and primary ovarian insufficiency (POI) and are instrumental in in vitro fertilization (IVF) procedures for medication dosing and predicting ovarian response. The growing awareness of reproductive health issues, the necessity for early and precise fertility diagnosis, and the increasing age of first-time pregnancies drive the demand for AMH tests. Technological advancements and expanding healthcare infrastructure further enhance accessibility and affordability. However, the limited awareness in low-resource settings and the high cost of tests, coupled with the need for standardized testing protocols, present challenges to market penetration. Moreover, technological integration for interpreting AMH levels and related fertility factors offers significant growth opportunities.

Point-of-care (POC) testing is increasingly preferred for its immediate results, enabling swift decision-making in clinical practice. These tests are designed for ease of use and rapid results, ideal for healthcare providers needing to streamline fertility evaluations. Self-check kits cater to individuals seeking privacy and convenience, providing an initial step in fertility investigation from home. Commercial labs serve clinicians and specialists with advanced diagnostic tools, ensuring efficiency and reliability for high-volume testing. Research and development (R&D) institutions demand high-sensitivity tests for advancing fertility and reproductive health research. The distribution channels are evolving, with a growing preference for online platforms that offer detailed product information and user reviews, catering to consumers seeking convenience and privacy.

In humans, AMH tests assess ovarian reserve and fertility potential, crucial for fertility treatments and reproductive health evaluations. In non-human primates, these tests assist in conservation efforts and breeding program management, providing insights into reproductive potential.

The key regions considered for the global Anti-Mullerian Hormone (AMH) Test Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. Asia-Pacific is a dominating region in the Anti-Mullerian Hormone (AMH) Test Market in terms of revenue. The market growth in the region is being attributed to factors including increasing healthcare expenditures and awareness. Also, the region lead with advanced healthcare infrastructure and significant R&D investments. Whereas, the market in Europe is anticipated to grow at the fastest rate over the forecast period fueled by enhancing healthcare infrastructures and policies.

Major market players included in this report are:
Abbexa Limited
Abcam PLC
Ansh Labs LLC
Athenese-Dx
Bio-Rad Laboratories, Inc.
Bio-Techne Corporation
bioMerieux S.A.
BioVendor - Laboratorni Medicina A.S.
Chengdu VACURE Biotechnology Co., Ltd.
CTK Biotech, Inc.
Cusabio Technology LLC
Eagle Biosciences, Inc.
Elabscience Bionovation Inc.
Epitope Diagnostics, Inc.
F. Hoffmann-La Roche Ltd.
The detailed segments and sub-segment of the market are explained below:
By Product:
POC Testing
Self-check Kits
By End-User:
Commercial Labs
Research & Development
By Distribution:
Offline Channels
Online Channels
By Use:
Human
Non-Human Primate
By Region:
North America:
U.S.
Canada
Europe:
UK
Germany
France
Spain
Italy
ROE
Asia Pacific:
China
India
Japan
Australia
South Korea
RoAPAC
Latin America:
Brazil
Mexico
Middle East & Africa:
Saudi Arabia
South Africa
RoMEA
Years considered for the study are as follows:
Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032
Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com